Study of RC-160 for Metastatic Breast Cancer
Author Information
Author(s): O'Byrne K J, Dobbs N, Propper D J, Braybrooke J P, Koukourakis M I, Mitchell K, Woodhull J, Talbot D C, Schally A V, Harris A L
Primary Institution: Imperial Cancer Research Fund Medical Oncology Unit, Churchill Hospital, Oxford, UK
Hypothesis
Can high-dose RC-160 effectively treat metastatic breast cancer?
Conclusion
High-dose RC-160 can reduce certain growth factor levels but is ineffective in managing metastatic breast cancer.
Supporting Evidence
- The treatment was well tolerated with no dose reductions required.
- No grade 3 or 4 toxicities were seen.
- A significant reduction in IGF-I levels occurred by day 7.
- Elevated prolactin levels in three patients fell to normal after treatment.
- A small but significant rise in fasting blood glucose levels was recorded.
Takeaway
This study tested a new treatment for breast cancer, but it didn't help the patients get better.
Methodology
The study involved administering high-dose RC-160 to 14 women with previously treated metastatic breast cancer and monitoring their response.
Limitations
No objective tumor responses were observed, and all patients showed disease progression within 3 months.
Participant Demographics
Participants were women aged 37 to 80 years, with a median age of 58.5 years.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website